Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: J Control Release. 2012 Jul 16;164(2):10.1016/j.jconrel.2012.07.010. doi: 10.1016/j.jconrel.2012.07.010

Fig. 1.

Fig. 1

Delivery of intravenously (iv) administered nanoparticles to the target tumor. (A)The majority of the administered nanoparticles end up in the non-target organs and only a small fraction reaches the target tumor. (B) The nanoparticles circulate in blood to reach target tumors by extravasation. The drug leaks out of the nanoparticles during circulation, and the majority of the nanoparticles end up in non-target organs. The nanoparticles reaching the target tumor face a tumor microenvironment different from that of normal tissues.